M&A Deal Summary

Bioverativ Acquires True North Therapeutics

On May 23, 2017, Bioverativ acquired life science company True North Therapeutics for 400M USD

Acquisition Highlights
  • This is Bioverativ’s 1st transaction in the Life Science sector.
  • This is Bioverativ’s largest (disclosed) transaction.
  • This is Bioverativ’s 1st transaction in the United States.
  • This is Bioverativ’s 1st transaction in California.

M&A Deal Summary
Date 2017-05-23
Target True North Therapeutics
Sector Life Science
Buyer(s) Bioverativ
Deal Type Add-on Acquisition
Deal Value 400M USD

Target

True North Therapeutics

San Francisco, California, United States
True North Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class product candidates for complement-mediated diseases. The company’s lead product candidate, TNT009, is designed to selectively inhibit a target in the classical complement pathway. True North’s antibody drug development is focused on the treatment of certain rare diseases mediated by the complement system.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Bioverativ

Waltham, Massachusetts, United States
Category Company
Sector Life Science
Employees350
DESCRIPTION

Bioverativ, Inc. is a global biotechnology company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2017) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal